Drugs / Mavrostobart
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05431270 | Aug 2022 → Dec 2027 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Phanes Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mavrostobart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05431270 ↗ |
| Known as | PT199 | “Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action.” NCT05431270 ↗ |
| Action | Inhibit | “is expected to completely inhibit CD73 enzyme activity.” NCT05431270 ↗ |
| Modality | Monoclonal antibody | “Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action.” NCT05431270 ↗ |